Study of polymorphisms in the interleukin-4 and IL-4 receptor genes in a population of Brazilian patients with multiple sclerosis

Arquivos de Neuro-Psiquiatria

Volumn 65, Issue 1, 2007, Pages 15-19

  Quirico Santos, Thereza ^a,b,d   Suppiah, Vijayaprakash ^a   Heggarty, Shirley ^a   Caetano, Regina ^b   Alves Leon, Soniza ^c   Vandenbroeck, Koen ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^c University Rio de Janeiro   (Brazil)

^d Instituto de Biologia   (Brazil)

Author keywords

Ethnicity; IL 4 receptor; Interleukin 4; Multiple sclerosis; Single nucleotide polymorphism

Indexed keywords

INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; BRAZIL; CONTROLLED STUDY; DISEASE COURSE; DISEASE PREDISPOSITION; ETHNICITY; FEMALE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MALE; MULTIPLE SCLEROSIS; POPULATION RESEARCH; PROMOTER REGION; RECEPTOR GENE; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 34147112312     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/S0004-282X2007000100005     Document Type: Article

References (26)

1. Hafler DA. Multiple sclerosis. J Clin Invest 2004;113:788-794.
2. Dyment DA, Ebers GC, Sadovnick AD. Genetics of multiple sclerosis. Lancet Neurol 2004;3:104-110.
3. Rivera VM. Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology 2005;64:2163.
4. Sotgiu S, Pugliatti M, Fois ML, et al. Genes, environment, and susceptibility to multiple sclerosis. Neurobiol Dis 2004;17:131-143.
5. Chaudhuri A, Behan PO. Multiple sclerosis is not an autoimmune disease. Arch Neurol 2004;61:1610-1612.
6. Lock CB, Heller RA. Gene microarray analysis of multiple sclerosis lesions. Trends Mol Med 2003;9:535-541.
7. Jansson A, Ernerudh J, Kvarnstrom M, Ekerfelt C, Vrethem M. Elispot assay detection of cytokine secretion in multiple sclerosis patients treated with interferon-b1a or glatiramer acetate compared with untreated patients. Mult Scler 2003;9:440-445.
8. Gimsa V, Wolf AS, Haas D, Bechmann I, Nitsch R. Th2 cells support intrinsic anti-inflammatory properties of the brain. J Neuroimmunol 2001;119:73-80.
9. Kawakami R, Raguchi J, Murata T, Puri RK The interleukin-13 receptor α2 chain: an essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway. Blood 2001;97:2673-2679.
10. Kelly BL, Locksley RM. Coordinate regulation of the IL-4, IL-13, and IL-5 cytokine cluster in Th2 clones revealed by allelic expression patterns. J Immunol 2000;165:2982-2986.
11. Sakagami T, Witherspoon DJ, Nakajima T, et al. Local adaptation and population differentiation at the interleukin 13 and interleukin 4 loci. Genes and Immunity 2004;5:389-397.
12. Hershey GK. IL-13 receptors and signalling pathways: an evolving web. J Allergy Clin Immunol 2003;111:677-690.
13. Mirel DB, Barcellos LF, Wang J, Hauser SL, Oksenberg JR, Erlich HA. Analysis of IL4R haplotypes in predisposition to multiple sclerosis. Genes and Immunity 2004;5:138-141.
14. Vandenbroeck K, Goris A. Cytokine gene polymorphisms in multifactorial diseases: gateways to novel targets for immunotherapy? Trends Pharmacol Sc 2003;24:284-289.
15. Heggarty S, Sawcer S, Hawkins S, et al. Agenome wide scan for association with multiple sclerosis in a N. Irish case control population. J Neuroimmunol 2003;143:93-96.
16. Kantarci OH, Goris A, Hebrink DD, et al. IFNG polymorphisms are associated with gender differences in susceptibility to multiple sclerosis. Genes and Immunity 2005;6:153-161.
17. Hackstein H, Bitsch A, Bohnert A, et al. Analysis of interleukin-4 receptor α chain variants in multiple sclerosis. J Neuroimmunol 2001;113: 240-248.
18. Vandenbroeck K, Martino G, Marrosu MG, et al. Occurrence and clinical relevance of an interleukin-4 gene polymorphism in patients with multiple sclerosis. J Neuroimmunol 1997;76:189-192.
19. Caballero A, Alves-Leon S, Papais-Alvarenga RM, Fernandez O, Navarro G, Alonzo A. DQB1*0602 confers susceptibility to multiple sclerosis in Afro-Brazilians. Tissue Antigens 1999;54:524-526.
20. Scarel-Caminaga RM, Trevilatto PC, Souza AP, Brito RB, Line SP. Frequencies of the -330 (T-G) Il-2 and -590 (T-C) IL-4 gene polymorphisms in a population from south-eastern Brazil. Eur J Immunogenetics 2002; 29:283-296.
21. McDonald WI, Compston A, EdamGoodkin GD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on diagnosis of multiple sclerosis. Ann Neurol 2001; 50:121-127.
22. Lublin FD, Reingold S.C. The National Multiple Sclerosis Society (USA), Advisory Committee on clinical trials of new agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis; results of an international survey. Neurology 1996;46:907-911.
23. Rockman MV, Hahn MW, Soranzo N, Goldstein DB, Wray GA. Positive selection on a human-specific transcription factor binding site regulating IL4 expression. Curr Biol 2003;13:2118-2123.
24. Compston A. The marvellous harmony of the nervous parts: the origins of multiple sclerosis. Clin Med 2004;4:346-354.
25. Cree BA, Khan O, Bourdette D, et al. Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology 2004;63:2039-2045.
26. Papais-Alvarenga RM, Miranda CM, Puccioni-Sohler M, et al. Optic neuromyelitis syndrome in Brazilian patients, J Neurol Neurosurg Psychiatry 2002;73:429-435.